The interdisciplinary team behind the most advanced BCI platform

OUR UNIQUE TEAM

Building neurotechnology that cannot be replicated

Paradromics team blends deep expertise in neurotechnology, engineering, data science, and proven go-to-market, Class III medical device experience.

Join our unique team

A male team member opening a machine while manufacturing the Paradromics Brain-Computer Interface Cortical Module

THE ROAD TO

Enabling neurotechnology

Founder and CEO Matt Angle, inspired by his research at Stanford, understood that a high-data rate, high-reliability brain-computer interface (BCI) could transform the scope and scale of brain-health applications.

2015

Matt established Paradromics headquarters in Austin, Texas for the plentiful BBQ and beer.

2015-image

2016-2018

Secured NIH and DARPA contracts to explore core technology and establish proof of concept.

2019

Medical device veteran James Burrows joined Paradromics as COO, shaping our neurotechnology roots into a product focused company preparing for launch.

2019-image

2020-2022

Pre-clinical demonstration of the highest channel count in vivo neural recording to date and the first chronic recordings from Connexus BCI.

20220-image

2023

Vikash Gilja, a tenured professor and early Neuralink employee, joined Paradromics as CSO, bringing strong expertise in machine learning and real-time neural decoding.

2023-image

2023

Established an office in Oakland, California focused on machine learning and data science. Received FDA breakthrough device designation for speech decoding.

2024

Received FDA breakthrough device designation for control of digital devices. Accepted into the FDA Total Product Life Cycle Advisory Program (TAP).

2024

Started pre-clinical studies needed for early feasibility study (EFS) FDA submission.